Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
51
datasets available to search
ShareScore release 0.9.0
Dataset results
51 results for “Central retinal vein occlusion”
Minocycline to Treat Central Retinal Vein Occlusion
ClinicalTrials.gov study NCT01468844. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
ClinicalTrials.gov study NCT01012973. IPD Sharing: Not stated. Countries: 10. Publications: 2.
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
ClinicalTrials.gov study NCT01225146. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
ClinicalTrials.gov study NCT04740931. IPD Sharing: YES. Countries: 22. Publications: 2.
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion
ClinicalTrials.gov study NCT01710839. IPD Sharing: Not stated. Countries: 1. Publications: 14.
Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
ClinicalTrials.gov study NCT01535261. IPD Sharing: Not stated. Countries: 18. Publications: 2.
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
ClinicalTrials.gov study NCT03981549. IPD Sharing: YES. Countries: 1. Publications: 3.
Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion
ClinicalTrials.gov study NCT04812977. IPD Sharing: NO. Countries: 1. Publications: 2.
NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
ClinicalTrials.gov study NCT01870427. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
ClinicalTrials.gov study NCT00088283. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
ClinicalTrials.gov study NCT00485836. IPD Sharing: Not stated. Countries: 0. Publications: 2.
Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion
ClinicalTrials.gov study NCT01448018. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
ClinicalTrials.gov study NCT03810313. IPD Sharing: YES. Countries: 20. Publications: 0.
Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept
ClinicalTrials.gov study NCT02880644. IPD Sharing: YES. Countries: 1. Publications: 13.
Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab
ClinicalTrials.gov study NCT01360385. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
ClinicalTrials.gov study NCT00406471. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Data from: Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion
Objectives: To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) agents and corticosteroids for the treatment of macular edema (ME) secondary to central retinal vein occlusion (CRVO). Design: Systematic review and network meta-analysis. Participants: Patients from previously reported randomized controlled trials (RCTs) comparing anti-VEGF and corticosteroids for the treatment of ME secondary to CRVO. Methods: Literature searches were conducted using PubMed, Medline, Embase, Cochrane Library, and clinicaltrials.gov until March 2017. Therapeutic effects were estimated using the proportions of patients gaining/losing ≥15 letters, best-corrected visual acuity (BCVA), and central retinal thickness (CRT). Treatment safety was estimated using the proportions of adverse events, namely increased intraocular pressure (IOP), cataracts, vitreous hemorrhage (VH), and retinal tear. The software ADDIS (version 1.16.8) was used for analysis. Treatment effect and safety of different drugs could be ranked based on simulation. Results: Eleven RCTs comprising 2060 patients were identified. Regarding patients gaining ≥15 letters, aflibercept and ranibizumab were significantly more effective than sham/placebo at 6 months. Regarding patients losing ≥15 letters at 6 months, ranibizumab showed significant improvement compared to dexamethasone. Aflibercept, bevacizumab, or ranibizumab showed greater improvements in BCVA than sham/placebo at 6 months. Intravitreal ranibizumab injection demonstrated greater CRT reduction than both sham and dexamethasone did. Dexamethasone had a higher risk of increased IOP than aflibercept and ranibizumab. Ranibizumab demonstrated a greater risk of cataracts than dexamethasone. Aflibercept and ranibizumab demonstrated low incidence of VH and retinal tear, respectively. Aflibercept had a slight advantage over ranibizumab as assessed by benefit-risk analysis. Conclusions: Anti-VEGF agents have advantages in the treatment of ME secondary to CRVO. Aflibercept and ranibizumab showed marked BCVA improvement and CRT reduction. Aflibercept may have a slight advantage over ranibizumab. The results of this study can serve as a reference for clinicians to provide patient-tailored treatment.
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
ClinicalTrials.gov study NCT00943072. IPD Sharing: Not stated. Countries: 5. Publications: 0.
A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
ClinicalTrials.gov study NCT00952614. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
ClinicalTrials.gov study NCT01231633. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.